Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: Analysis of four randomized trials

T. Reiman, R. Lai, A. S. Veillard, E. Paris, J. C. Soria, R. Rosell, M. Taron, S. Graziano, R. Kratzke, L. Seymour, F. A. Shepherd, J. P. Pignon, P. Sève

Research output: Contribution to journal › Article › peer-review

69 Scopus citations

Fingerprint

Dive into the research topics of 'Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: Analysis of four randomized trials'. Together they form a unique fingerprint.

Medicine & Life Sciences